DHEA dosage

Protocol

1. 1

   Measure the dose

   Typical DHEA dose is 25 mg. Use a weight-based calculator for individual adjustments.

   Open tool →
2. 2

   Set the frequency

   Administer daily, typically morning. Half-life of 12 hours anchors the dosing interval.

   Open tool →
3. 3

   Cycle if needed

   No formal cycling; long-term continuous dosing is empirical

   Open tool →
4. 4

   Monitor for side effects

   Watch for: acne; oily skin; hirsutism (women); gynecomastia (men, higher doses). Stop or reduce dose if tolerability breaks down.

Why this dose

Steroid prohormone converted intracrinologically to testosterone and estrogens in target tissues; also exerts direct effects via sigma-1 receptor, GABA-A modulation, and glucocorticoid receptor interaction.

The typical 25 mg dose is the figure most commonly used in published protocols for DHEA. Treat the label as a starting point: body weight, training status, sleep, diet, and concurrent medications all shift the effective dose-response curve in real users.

How to administer

DHEA is administered via the oral, vaginal, topical routes. Oral dosing is straightforward: take with water, with or without food unless specifically noted.

Onset of action runs around 1 hour after administration. Peak effect lands near 1 hour post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: DHEA half-life ~30 minutes; circulating DHEA-S half-life 12 to 24 hours, the more stable readout for monitoring

Cycling and tolerance

No formal cycling; long-term continuous dosing is empirical

The cycling rationale for receptor-active compounds is partly empirical and partly mechanistic: continuous high-dose stimulation can downregulate target receptors or accelerate negative-feedback loops on endogenous production. Built-in off-periods give the system time to resensitize before the next phase, which preserves the effective dose-response over a longer arc.

Effects to expect at typical dose

• Adrenal androgen precursor; serum DHEA-S declines progressively after the third decade of life
• OTC dietary supplement in US under DSHEA 1994; prescription in EU, UK, Canada, Australia
• FDA approved as Intrarosa (6.5 mg vaginal insert) for postmenopausal dyspareunia in 2016
• Acts as tissue-specific prohormone converted intracrinologically to testosterone and estrogens
• Best evidence: adrenal insufficiency replacement and vaginal atrophy; weaker on cognition and longevity
• WADA banned in competitive sport; banned in NCAA, MLB, NFL, IOC settings

Side effects and interactions

Common side effects

• acne
• oily skin
• hirsutism (women)
• gynecomastia (men, higher doses)
• irritability

Notable interactions

• warfarin (moderate): case reports of altered INR; monitor
• estrogens (HRT) (moderate): additive estrogenic effect via conversion; monitor
• insulin (minor): may improve insulin sensitivity slightly; monitor glucose
• anastrozole (minor): may reduce DHEA-derived estrogen; clinical relevance unclear

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full DHEA profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

banned

DEA / Rx

OTC supplement in US (not scheduled); Rx in EU, UK, Canada, Australia

Pregnancy

Contraindicated in pregnancy

Legal status

OTC supplement in US (DSHEA 1994); prescription in EU, UK, Canada, Australia

Do not use if

• hormone-sensitive cancer (breast, ovarian, prostate)
• active liver disease
• uncontrolled lipid disorder
• pregnancy and lactation

Related research